The serum and red blood cell (RBCs) disposition of epirubicin (EPR) after intravenous bolus injection without and with coadministered quinine (Q U I) was investigated in patients undergoing a cyclic chemotherapy with EPR. QUI possesses a statistical significant influence on the EPR serum concentrations and, as a consequence, on the pharmacokinetic parameters for the initial distribution phase of EPR. Within the first 15 min after administration, EPR was distributed from the central com partiment distinctly faster in compare to the control, when QUI was preadministered (tl/2 = 6 min for the control group and tv2 = 3 min with QUI; -46% , p < 0.05). Yet, in the beta-phase when drug-elimination predominates, no statis tical significant influence of QUI in regard to EPR serum and RBC concentrations could be observed. Half-life of elimination was 9.5 h for the control group and 8.6 h for the QUI group (-10% ). The mean initial serum concentration (c0) was reduced significantly by QUI from 7359 ± 506 ng/ml to 4351 ± 1682 ng/ml (-4 2 % . p < 0.005). Furtherm ore. QUI caused a reduction of the serum bioavailability of EPR (expressed as /4 t/Co_24-values) from 3404 ± 1008 ng/ml x h to 2359 ± 1073 ng/ml x h (-3 1 % , p < 0.05). Vd and Vdß were increased at about 90% and the mean total body clearance was accelerated from 45.3 to 148.7 ml/min, but due to the large standard deviations the calculated difference for these parameters was not statistically significant. In the observed time interval of 24 h, the red blood cell coefficient of distribution /cR B c °f EPR was lower if Q U I was coadministered (£ rb c = 1-25 ± 0.12 for the control group k RBC = 1.15 ± 0.13 under QU I; p < 0.04). The results point out that QUI induces an accelerated distribution of E PR from the blood into the tissue and that QUI additionally may have influence on the red-blood cell partitioning of EPR.
Introduction
Anthracyclines remain the most single chem o therapeutic agent in the treatment of advanced breast cancer, with response rates between 40% to 50% in previously untreated patients. Epirubicin (EPR), the 4'-epimer of doxorubicin*, represents a well established representative of this group of antineoplastic agents, which seem s to have lower side effects as cardiotoxicity or myelosuppression at equal doses (Weenen et al., 1986) .
A common form of multidrug resistance (M DR1) in human cancer is associated with the expression of the MDR1 gene, which appears to be one of major impediment to more successful cancer chemotherapy (Pastan et al., 1987) . The MDR1 gene regulates the activity of P-glycoprotein (GP170), which regulates the efflux of cyto toxic com pounds from the cell. A possibility to increase the response rate of the tumor is the com bination of an antineoplastic agent with a chemosensitizer, which binds to GP170 and is capable of modulating the overexpression of P-glycoprotein by retarding the drug efflux from the tumor cell (Safa 1988 ). For EPR the coadministration of a chem osensitizer such as R-verapamil** (Mross et al., 1993a (Mross et al., , 1993b Scheithauer et al., 1993; Czejka * (1 5, 2, 3, 4.6, 5, trihydroxy-10-methoxy-6 ,11 -dioxonaphthacen-1-yl-3-amino-2,3,6-trideoxy-alpha-L-lyxopyranosid. (Young et al., 1981) .
The chemotherapeutic agent quinine* (Q U I), and its optical isomer quinidine** (a class 1 A anti arrhythmic agent) are considered to interact with a wide range of drugs such as propanolol or flecainide (Gibaldi, 1993) and have been shown to re verse MDR1 of EPR in different in vitro models (D alton et al., 1993; Tsuruo et al., 1984) . Both iso mers appear to have equal activity in reversing re sistance, but QUI is less toxic as quinidine and the therapeutic index for QUI may be superior in the clinical setting (Lehnert et al., 1991) .
Pharmacokinetic data assessment represents a very useful method to demonstrate a chemosensitizing effect based on drug interaction in regard to drug metabolism and/or distribution. Therefore in the present pilot trial, the concentrations and pharmacokinetics of unbound EPR in serum and red blood cells (a subcompartment of the blood for drugs of the anthracycline family) were studied under the influence of coadministered QUI and compared (as a cross over design) with the control group without QUI.
Materials and Methods

Chemicals
All used solvents were from HPLC-grade purity (Merck, Darmstadt, Germany). Isoton-II was ob tained from Heilige (Vienna, Austria), ascorbic acid from Riedel de Haen (Hannover, Germany).
Drugs and administration
EPR (Farmorubicin; Farmitalia Carlo Erba, Mi lano, Italy) was administered as a 2 min intrave nous bolus (high dose of 90 mg/m2 body surface). Treatment was repeated after a 4 week interval provided hematological parameters were satisfac tory, whereby QUI was given three times day p.o.
* (85,9 /?)-6'-methoxycinchonan-9-ol). ** (8/?.9S)-6'-methoxycinchonan-9-ol).
in capsules which had been produced in the hospi tal pharmacy of the hospital Rudolfstiftung (each gelatin capsule containing 250 mg QUI; 1000 mg total individual dose, for three days prior to EPR bolus).
Human subjects
Six female patients with histologically confirmed advanced mamma carcinoma entered the study. All patients had a WHO performance status of 1 with no renal or hepatic impairment as judged by standard biochemical parameters. The age of the patients ranged from 50 to 56 years (x = 52.6 ± 2.4 y) and their body weight was from 51 to 68 kg (x = 63.2 ± 6.7 kg). All patients had given in formed consent before entering the study, in ac cordance with the guidelines of the ethics commit tee of the University of Vienna.
Analytical procedure
Blood samples of 5 ml were collected in EDTAimpregnated vacutubes at the following times: 0 , 3, 5, 10, 15 and 30 min and 1.0, 2.0, 4.0, 6.0 and 24 h after administration. An aliquot of 2.7 ml was mixed with 0.3 ml of ascorbic acid (1 mg/ml Iso ton) for stabilization of EPR and vortexed for 2 min under protection from light to avoid photode gradation of the drug. Separation of red blood cells from serum was performed as described (Czejka et al., 1992a (Czejka et al., , 1992b and EPR was quanti fied in the samples by high performance liquid chromatography using fluorimetric detection (Czejka et al., 1988) . Analysis of blood samples (serum. RBCs) was performed within one week after collection in order to prevent loss of EPR during frozen storage. 
Biometric data assessment
The percental amount of EPR which is present in serum and RBCs, respectively, was obtained according to Eqns (2) or (3):
Results
Serutn and RBC concentrations
After bolus of EPR without QUI, the mean con centration time curve declined in a biexponential manner with a rapid phase of initial distribution followed by a phase of terminal elimination. ( any significant difference. The mean concentra tion-time curve of EPR for the RBCs declined very similar compared to serum: for a better over view the RBC concentration-time curves are not depicted in Fig. 1 (but data are presented in Table I ).
The percent ratio of EPR between serum and RBCs with and without QUI is summarized in Table I 
Although this reduction of k RBC is of rather
little order of magnitude ( -6 .2 %), this change was statistically significant with a level of probability of p < 0.05 for serum and p < 0.04 for kRBC. 
Ph a rn mcokinetics
The basic pharmacokinetic parameters of EPR in serum (using an open two-compartment model for calculation) are presented in Table II . As de scribed above, QUI causes an accelerated distribu tion of EPR during the a-phase. The mean initial serum concentration (c0) is reduced at 41.2% from 7085 ng/ml to 4816 ng/ml with a level of prob ability of p < 0.005. The intercepts of the hybrid constants (A , B) with the y-axis are influenced by Q UI in a similar order of magnitude: "A " (repre senting the a-phase) decreases at 32% (p < 0.05) and "B " (representing the ß-phase) at 56.3% (p < 0.02). These two parameters indicate an ac celerated drug distribution, if QUI is coadminist ered. The half-life of distribution was 3.1 ± 2.8 min for the Q UI group, this was an acceleration of about 50% in compare to the control (6.6 ± 3.8 min).
The total body clearance was accelerated by QUI from 45.3 to 148.7 ml/h; this is an increase of more than 2 2 0 %. but due to the high standard deviation of the data set especially in the QUIgroup, this increase was not statistically significant.
The volume of distribution (Kd) and the Vd in the ß-phase were increased by QUI at about 90%, too, but as in the case of clearance, significancy was very weak.
The most important pharmacokinetic parame ter, representing the availability of a drug in the central compartiment. is the area under the con centration-time curve (A U C ).
The mean AU C )ast of EPR was diminished un der Q U I coadministration from 3404 ± 1008 to A nother explanation for this drug interaction might base on a changed hepatic metabolism of EPR as QUI is known to inhibit a certain range of drugs. This is a result o f the high affinity be tween Q UI and cytochrome P2D 6, an isoenzyme of cytochrome P-450, which mediates the oxidative metabolism of drugs in hepatocytes (Gibaldi et al., 1993) . Cytostatics from the anthracycline family undergo extensive hepatic metabolism for phase-I and especially for phase-II reactions. So it would be possible, theoretically, that QUI induces the he patic enzym es which are responsible for EPR-metabolism leading to lower serum concentrations of EPR. In such a case the determination of the m e tabolites of EPR in faeces (glucuroni-dation) could verify this theory.
A s cytochrome activity (cytochrome P-420) can be observed at a certain extent in RBCs, too, (Cossum et al., 1988) and antineoplastic agents from the anthracycline-type own a high affinity towards RBCs (Boroujerdi et al., 1990a (Boroujerdi et al., , 1990b De Flora et al., 1986) , the decrease of EPR concentrations inside the blood cells could amplify the observed Q U I-effect. Increased metabolism of EPR inside the RBCs caused by Q UI can be excluded after evaluation of the chromatograms.
Further it has to be considered that drug in teractions also may base on competitive protein binding or red-blood cell partitioning in those cases, when a drug owns a high affinity to serum proteins and/or RBCs.
The study had to be finished after six patients because no tumor response could be stated by QUI (this observation is in accordance with the findings of Bisset et al. (1994) . Additionally it must be pointed out that the high dose of QUI, which is necessary to obtain a definitive effect for such a drug interaction, leads to high serum concentra tions ( 1 -5 [ig/ml) with particular severe side ef fects. In this pilot we observed typical "cinchonism " with vomiting, dizziness and tinnitus. For two patients it was necessary to perform audio metric measurements due to QUI toxicity.
The present results demonstrate, that the ob served in vitro effect of an increased cell-uptake of EPR when combined with QUI takes place in vivo, too, but only at a small extent. If drug efflux from the cell is inhibited continuously, the serum concentrations of EPR must be lower significantly for the whole observed period (24 hours) and not only for the first 30 min after administration. In compare to the control group, the slightly di minished concentrations of EPR in RBCs under Q UI indicate a certain change in RBC-partitioning, but absolute no significant difference in the metabolic pathway of EPR (reduction of the ketofunction in position 13 by aldo-ketoreductase ac tivity) could be observed.
